49
Pharmacotherapy of Migraine Dr Manukumar Post graduate Dept of Pharmacology VMMC & Safdarjung hospital

Pharmacotherapy of migraine

Embed Size (px)

DESCRIPTION

migraine pathophysiology, treatment,

Citation preview

Page 1: Pharmacotherapy of migraine

Pharmacotherapy of Migraine

Dr ManukumarPost graduate

Dept of PharmacologyVMMC & Safdarjung hospital

Page 2: Pharmacotherapy of migraine

• Outline• Migraine • Pathophysiology

TheoriesVascular theoryNeurogenic theoryNeurovascular theory

• Acute treatment of migraine Non-specific treatmentSpecific treatment

• Preventive treatment of migraine• Newer targets and drugs

Page 3: Pharmacotherapy of migraine

• Second most common type of primary headache• Migraine is chronic neurological disorder

characterized by episodic attacks of headache and associated symptoms.

• Migraine prevalence is approximately 18% in females and 6% in males.

• The brain of the migraineur is particularly sensitive to environmental and sensory stimuli.

First description of migraine with visual aura.

Migraine headache

Page 4: Pharmacotherapy of migraine

• A recent economic model estimated that losses due to decreased productivity are roughly $1.9 million for a company with 10,000 employees

Page 5: Pharmacotherapy of migraine

Pathophysiology of migraine

• Vascular theory-attributes the phenomenon of vasodilatation.

• Neurogenic theory- neuronal events, cortical spreading depression.

• Third theory - accommodate vascular modifications with neuronal dysfunction.

Page 6: Pharmacotherapy of migraine

Vascular theory

• Harold G Wolff first one to explain• Vasoconstriction and ischemia accounts for

symptoms of migraine aura,• Reactive vasodilatation activate primary

sensory neurons.• Therapies provides evidence for this theory.

Page 7: Pharmacotherapy of migraine

Cortical spreading depression• NMDA receptors involved in the genesis and propagation of

CSD. CSD was blocked by NMDA receptors antagonists in various experimental models

Long lasting depression of neuronal activity.

Page 8: Pharmacotherapy of migraine

Cortical spreading depression

perivascular trigeminal and parasympathetic nerve activation, release of vasodilator mediators, CGRP, neurokinen A, substance P

(pain signal)trigeminal ganglion trigeminal nucleus caudalis trigeminocervical complex

Page 9: Pharmacotherapy of migraine
Page 10: Pharmacotherapy of migraine

General diagnostic criteria of migraine.

Page 11: Pharmacotherapy of migraine
Page 12: Pharmacotherapy of migraine

Pharmacological treatment of migraine includes

Acute (abortive) treatmentPreventive (prophylaxis) treatment

Page 13: Pharmacotherapy of migraine
Page 14: Pharmacotherapy of migraine

Goals for acute treatment

1. Treat attacks rapidly and consistently without recurrence.

2. Restore the patient’s ability to function. 3. Minimize the use of back-up and rescue

medications. 4. Be cost-effective for overall management.5. Have minimal or no adverse events.

Page 15: Pharmacotherapy of migraine

Non-specific Rx of migraine“NSAIDs”

• PGE2 and PGI2 reduce the threshold to stimulation of nociceptors, causing peripheral sensitization

• CGRP release from the terminals of the trigeminal sensory neurons is modulated by PGE2

• Blockade cyclooxygenase (COX) and hence reduced synthesis of PG

Page 16: Pharmacotherapy of migraine

Forest plot of comparison: Ibuprofen 400 mg versus placebo

• Cochrane Database of Systematic Reviews 2010, Issue 10. Art. No.: CD008039

26% 12%

Page 17: Pharmacotherapy of migraine
Page 18: Pharmacotherapy of migraine

• Postgrad Med J 2004;80:720–723.

Page 19: Pharmacotherapy of migraine

Anti-emetics/caffeine – combination with NSAIDs

• Metoclopramide effective for nausea and vomiting associated with certain types of headaches.

• D2 antagonistic action might be responsible for relieve of migraine

• Caffeine, Block the adenosine receptor, Vasoconstricting action.

Page 20: Pharmacotherapy of migraine

Efficacy and Safety of Acetaminophen, Aspirin, and Caffeine in Alleviating Migraine Headache Pain: Double-blind,

Randomized, Placebo-Controlled Trials

• Arch Neurol. 1998;55(2):210-217

Page 21: Pharmacotherapy of migraine

Specific acute treatment

• Triptan-Sumatriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, almotriptan & frovatriptan

• Selective activity on 5-HT1B/1D agonist.• Mechanisms of action

Cranial vasoconstrictionModulating neurotransmitter release from

neuronal terminals.

Page 22: Pharmacotherapy of migraine
Page 23: Pharmacotherapy of migraine

• The triptans -preventing the peripheral release of vasoactive peptides (CGRP), reduce PPE.

• Also inhibit the abnormal activation of peripheral nociceptors.

• The 5-HT1D receptor-selective agonist PNU-142633 showed greater potency than sumatriptan in blocking electrically induced PPE, and had little to no detectable vascular activity in carotid, meningeal arteries

Page 24: Pharmacotherapy of migraine

Adverse Effects and Contraindications

• coronary artery vasospasm, transient myocardial ischemia, atrial and ventricular arrhythmias, MI

• Irritation at the site of injection. The most common side effect of sumatriptan nasal spray is a bitter taste.

• Contraindicated- coronary artery disease , history of stroke or transient ischemic attacks, cerebrovascular or peripheral vascular disease,

Page 25: Pharmacotherapy of migraine

• J Manag Care Pharm. 2005;11(5):394-402

Page 26: Pharmacotherapy of migraine
Page 27: Pharmacotherapy of migraine

Ergot alkaloids

• The pharmacological effects of the ergot alkaloids are varied and complex; partial agonists or antagonists at serotonergic, dopaminergic, and adrenergic receptors

• Ergot alkaloids at 5-HT1B/1D receptors likely mediate their acute anti-migraine effects

Page 28: Pharmacotherapy of migraine

Selection of patients – ergot

• Which patients?Patients requiring migraine-specific therapyPatients established on ergotamine

• Special cases Patients with very long attacks Patients with frequent headache recurrence

Page 29: Pharmacotherapy of migraine

Adverse Effects and Contraindications of Ergot Alkaloids

• Nausea and vomiting, due to a direct effect on CNS emetic center.

• contraindicated in pregnant, peripheral vascular disease, coronary artery disease, hypertension, impaired hepatic or renal function

• In contrast to triptans, the contractile effect of ergotamine in the human isolated coronary artery is long- lasting and persists even after repeated washings

Page 30: Pharmacotherapy of migraine

• Comparison of vasoconstriction action of ergotamine and triptan

• MaassenVanDenBrink et al., 1998

Page 31: Pharmacotherapy of migraine

Preventive treatment of

migraine

Page 32: Pharmacotherapy of migraine

Indications

1. Two or more attacks per month that significantly interfere with the patient’s daily routine activity

2. An unsatisfactory response to acute therapy3. contraindication to acute treatments and

adverse effects (AEs) related to them.4. Uncommon migraine conditions, including

hemiplegic migraine, migraine with prolonged aura or migrainous infarction.

Page 33: Pharmacotherapy of migraine

The potential mechanisms of migraine preventive medications

• Raising the threshold to migraine activation by stabilizing a more reactive nervous system

• Enhancing antinociception• Inhibiting CSD• Inhibiting peripheral and/or central

sensitization• Blocking neurogenic inflammation

Page 34: Pharmacotherapy of migraine

Preventive medication

Page 35: Pharmacotherapy of migraine

Antidepressants

• Amitriptyline alters the 5-HT synthetic rate at the dorsal raphe nucleus.

• Enhancement of the pain threshold produced by AMT seems to be mediated by sodium channels, L-type calcium channels inhibition.

• Chronic daily administration of AMT suppresses CSD, whereas acute treatment is ineffective.

Page 36: Pharmacotherapy of migraine

50% reduction in migraine headaches TCA Vs placebo

Jackson, JE., et al. (2010). Tricyclic antidepressants and headaches: systematic review and meta-analysis. Bmj, 341(oct20 1)

Page 37: Pharmacotherapy of migraine

• SSRI- In a recent review, SSRIs resulted as efficacious as placebo for preventing migraine and less effective than TCA.

• In a randomized controlled study fluoxetine, venlafaxine, duloxetine versus placebo, reduced frequency of migraine attacks, but not significant.

Page 38: Pharmacotherapy of migraine

Beta blocker

• Clinical findings support the efficacy of propranolol, timolol, atenolol, nadolol and metoprolol in migraine preventive treatment.

• Exhibit high affinity for 5-HT receptor( 1a, 1b/d,2a)

• propranolol blocked CSD in rats, without altering regional cerebral blood flow and systemic arterial blood pressure

Page 39: Pharmacotherapy of migraine

Cont…

• 53 studies including meta-analysis involving 2403 patients who are treated with either propranolol and/or placebo , propranolol yielded 44% reduction in migraine attack.

• Two clinical trials valproic acid compared with propranolol, in both trials efficacy is identical.

Page 40: Pharmacotherapy of migraine

Anti-epileptics

• An unbalanced activity b/w excitatory glutamatergic transmission and GABAnergic inhibition, abnormal activation of voltage-operated ionic channels; Na , Ca channels , has been postulated in these two pathological condition.

• “Valproate, topiramate”, gabapentin, lamotrigine are best for prophylaxis.

Page 41: Pharmacotherapy of migraine

Cont..• VPA, TPM, Effect on voltage gated Na channels

modify the neuronal excitability(CSD), role of Na channels are proved in FHM.

• VPA reduces the neurogenic inflammation, plasma extravasation (Cutrer et al., 1997), possibly through a GABA-mediated mechanism

Page 42: Pharmacotherapy of migraine

Calcium channel blockers

• In an experimental model of neurogenic inflammation, blockade of L-type channels attenuates dural vasodilatation.

• flunarizine could exert its antimigraine effect by reducing neural NO synthase (NOS) activity

• In a double- blind study, flunarizine 5 mg/day was as effective as propranolol 160 mg/day in reducing the attack frequency.

Page 43: Pharmacotherapy of migraine

Newer targets and drugs

• Non-triptan 5-HT1 agonist, 5-HT1D agonists (PNU-109291 and PNU- 142633)

are potent inhibitors of dural plasma protein extravasation (PPE)

LY334370, which is a selective 5-HT1F agonist, inhibits single cell firing in the trigeminal nucleus caudalis (TNC)

Page 44: Pharmacotherapy of migraine

CGRP antagonist-BIBN4096BS(olcegapant)

• CGRP mediates dilation of cerebral vasculature and increases in cerebral blood flow.

• CGRP-induced vasodilation can activate nociceptors on cerebral vessels.

• In humans, intravenous human CGRP administration induces migraine-like headache in susceptible migraineurs

Page 45: Pharmacotherapy of migraine
Page 46: Pharmacotherapy of migraine

CGRP Antagonist BIBN 4096 BS(olcegapant) Vs placebo

• N Engl J Med. 2004 Mar 11;350(11):1104-10

Page 47: Pharmacotherapy of migraine

Nitric oxide synthase inhibitor

• An intravenous infusion of nitroglycerin (NTG) releases NO, causes migraine in more than 60% of migraineurs , and activates trigeminal neurons in experimental animals.

• In a small RCT, 546C88, a non-selective NOS inhibitor, was administered intravenoulsy to migraineurs during an acute attack (Lassen et al., 1998). The 2-hr headache response rate was 67% (10/15) on 546C88 versus 14% (2/14) on placebo

Page 48: Pharmacotherapy of migraine

compound Treatment class Clinical phase

Telcagepant [MK0974)-

CGRP receptor antagonist Phase 111

Olcegepant [BIBN4096BS)- CGRP receptor antagonist phase II

B144370- CGRP receptor antagonist phase II

Lasmiditan 5-HT 1F receptor agonist Phase 111

Tezampanel (LY-293558) AMPA and kainate receptor antagonist phase 111

Page 49: Pharmacotherapy of migraine